Management


Gregory J. Flesher

Gregory J. Flesher | President and Chief Executive Officer


Mr. Flesher has served as the President, Chief Executive Officer and a member of the Board of Directors of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017.  Prior to the acquisition, Mr. Flesher served as Chief Executive Officer and a member of the Board of Directors for Otic Pharma, Ltd. from 2015 to 2017.  Mr. Flesher has over 20 years of pharmaceutical industry experience and has been closely involved with several successful drug development programs that have resulted in multiple product approvals and commercial launches in the U.S. and Europe.  Prior to Otic Pharma, Mr. Flesher served as Senior Vice President of Corporate Development and Chief Business Officer, and other executive management roles at Avanir Pharmaceuticals, Inc. from 2006 to 2015.  Mr. Flesher previously served in various sales, marketing, and clinical development roles at InterMune, Inc., Amgen, Inc., and Eli Lilly and Company from 1995 to 2006.  Mr. Flesher earned his Bachelor of Science in Biology from Purdue University and studied Biochemistry and Molecular Biology at Indiana University School of Medicine.

Christine G. Ocampo

Christine G. Ocampo CPA | Chief Financial Officer and Chief Compliance Officer


Ms. Ocampo has served as the Chief Financial Officer and Chief Compliance Officer of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017.  Prior to the acquisition, Ms. Ocampo served as Chief Financial Officer and Chief Compliance Officer for Otic Pharma from 2015 to 2017.  Ms. Ocampo has over 25 years of accounting and finance experience, including over 14 years as the head of Finance for publicly-traded companies in the healthcare industry.  Prior to Otic Pharma, Ms. Ocampo served as Chief Accounting Officer, Vice President of Finance, Chief Compliance Officer and other executive management roles at Avanir Pharmaceuticals, Inc. from 2007 to 2015.  Ms. Ocampo previously served as Senior Vice President, Chief Financial Officer and Chief Accounting Officer and other finance leadership positions at Cardiogenesis Corporation (now CryoLife, Inc.), a publicly-traded medical device company, from 1997 to 2006.  Prior to Cardiogenesis, Ms. Ocampo served as an auditor for Ernst & Young LLP.  Ms. Ocampo graduated with a Bachelor of Arts in Accounting from Seattle University and is a licensed Certified Public Accountant.

Catherine C. Turkel

Catherine C. Turkel PharmD, MBA, PhD. | Chief Development Officer


Dr. Turkel has served as the Chief Development Officer of Novus Therapeutics, Inc. since the acquisition of Otic Pharma, Ltd. by Novus Therapeutics (formerly Tokai Pharmaceuticals, Inc.) in May 2017.  Prior to the acquisition, Dr. Turkel served as Chief Development Officer for Otic Pharma from 2015 to 2017.  Dr. Turkel has more than 30 years of combined clinical practice and drug development experience and is currently responsible for leading all preclinical, clinical, regulatory, quality and pharmaceutical development functions at Novus.  Dr. Turkel has successfully led global development project teams resulting in multiple registrations of new drug treatments around the world.  Prior to Otic Pharma, Dr. Turkel held several R&D leadership positions at Allergan, Inc., including Vice President of Clinical Development for Neurology, Urology, and Pain, Vice President of Global Medical Affairs, and other positions from 1998 to 2015.  Prior to Allergan, Dr. Turkel served as Director of Drug Development, Regulatory Affairs and Data Management at Cypros Pharmaceuticals from 1995 to 1998.  Dr. Turkel’s industry tenure also includes past positions at IVAC Corporation, California Clinical Trials, and Siemens Infusion Systems as well as many years as a hospital based critical care pharmacist.  Dr. Turkel holds a Doctor of Pharmacy from the University of the Pacific, an MBA from the University of California, Irvine, and a Doctor of Philosophy in Business from Capella University.